8-K: Coya Therapeutics Announces Board Leadership Transition

Coya Therapeutics founder Dr. Howard Berman steps down as Executive Chairman, with industry veteran Mark H. Pavao appointed as an independent director.

Summary

• Dr. Howard Berman resigned from the Board of Directors and his position as Executive Chairman, effective April 1, 2026.
• The departure is part of a planned CEO transition process initiated in November 2024.
• Mark H. Pavao, a biopharmaceutical executive with over 30 years of experience, was appointed as an independent director effective April 1, 2026.
• Dr. Berman will receive a prorated 2026 bonus at 100% of target and COBRA premium waivers through March 31, 2027.
• Dr. Berman's unvested stock options will continue to vest for 12 months, and the exercise period for vested options is extended to two years post-separation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while the loss of a founder is significant, the transition is orderly, planned, and brings in experienced commercial leadership to support the company's next phase of growth.

Positives

• The transition appears orderly and follows a previously established CEO succession plan.
• Appointment of Mark H. Pavao brings significant commercialization and global biopharmaceutical strategy experience to the Board.
• The company maintains continuity in its leadership team under CEO Dr. Arun Swaminathan.
• The company is advancing its lead asset, COYA 302, toward a Phase 2B data readout.

Negatives

• Loss of the company founder from the Board of Directors.
• The company incurs additional costs related to the separation agreement, including bonus payouts and COBRA premium waivers.

Risks

• Potential disruption during the transition of board leadership.
• Reliance on the success of the lead asset, COYA 302, in the ongoing ALSTARS Phase 2 trial.
• The company is a clinical-stage entity and remains subject to the inherent risks of drug development and regulatory approval.

Future Outlook

The company continues to focus on its clinical pipeline, specifically the ALSTARS Phase 2 trial for COYA 302, and is transitioning toward a commercial-stage focus with the addition of new board expertise.

Management Comments

• Arun Swaminathan, Ph.D.: 'Dr. Berman's entrepreneurial spirit and scientific foresight have been instrumental in guiding Coya... I am personally thankful for his mentorship.'
• Dr. Howard Berman: 'The company is in very capable hands with [Arun Swaminathan] as CEO.'
• Mark H. Pavao: 'I am impressed by Coya's science and clinical progress, which positions the company to make a meaningful impact for patients.'

Industry Context

StockSavvy.ai notes that board transitions in clinical-stage biotech companies are common as firms shift from R&D-heavy foundations to commercialization-ready structures. The addition of a director with deep commercial experience suggests Coya is preparing for potential late-stage trial success and market entry.

Comparison to Industry Standards

• The separation terms for the founder are consistent with standard executive transition agreements in the biotech sector.
• The appointment of an independent director with 30+ years of experience aligns with best practices for governance in publicly traded clinical-stage companies.

Management Changes

Corporate Governance

Legal Proceedings

• None mentioned.

Related Party Transactions

• None mentioned.

Stakeholder Impact

• Shareholders: Transition signals a shift toward commercialization.
• Employees: Continuity in leadership under the existing CEO.

Next Steps

• Completion of the ALSTARS Phase 2 trial for COYA 302.
• Evaluation of committee assignments for the new director, Mark H. Pavao.

Key Dates

Recommendation

The filing represents a routine, planned leadership transition. While the addition of commercial expertise is positive, the stock's performance remains primarily tied to the upcoming clinical trial data for COYA 302 rather than board-level changes.

Keywords

Coya Therapeutics, COYA, Biotech, Board Transition, ALS, Neurodegenerative, Clinical Trials, Executive Change